| Expression of HNF3 beta led to significant growth reduction, proliferation arrest, apoptosis, and loss of clonogenic ability, suggesting additionally that HNF3 beta is a novel tumor suppressor in lung cancer. | lung, |
| FOXA2 identified as a novel tumor suppressor in pancreatic cancer. It is regulated directly by miR-199a. | pancreatic, |
| FOXA2 may act as a tumor suppressor and inhibit the epithelial-mesenchymal transition of endometrial cancer cells. | endometrial, |
| USF1 acts as a positive transcription factor which binds to the basal promoter thus ensuring SLC25A13 gene expression in a wide range of tissues. The role of FOXA2 is different, working as an activator in hepatic cells. As a tumour suppressor, FOXA2 could be responsible for SLC25A13 high expression levels in liver and its downregulation in hepatocellular carcinoma. | liver, |
| The pattern of FOXA2 mutations and expression in tumors suggests complex regulation and a haploinsufficient or dominant-negative tumor suppressor function. | None |
| Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas. | None |